| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3998302 | Surgical Oncology | 2007 | 8 Pages |
Abstract
SummaryNeuroblastomas continue to remain a clinical challenge, despite advances in multimodal therapy. Currently, studies are aimed at novel targets for neuroblastoma directed toward poor prognostic indicators such as the MYCN oncogene and marked angiogenesis. There have also been recent discoveries in neuroblastoma pathogenesis involving epigenetic regulation and retinoic acid therapy. Understanding the intricate complexities of this tumor may lead to innovative agents for more effective combinational therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Titilope A. Ishola, Dai H. Chung,